It is made available under a CC-BY-NC 4.0 International license .

e: Comparative performance of COVID-19 Test Methods in Healthcare Workers during the Omicron ve
ve
t hors: Emma Tornberg, BS; Alexander Tomlinson, BS; Nicholas T.T. Oshiro; BS, Esraa Derfalie, RN; rcel E. Curlin, MD.
hor Affiliations: Department of Medicine, Division of Infectious Diseases, Oregon Health and
ences University, Portland, OR, USA
respondence and Reprint Requests to: Emma Tornberg, MD candidate, tornberg@ohsu.edu
nning Head: Text
eles and Figures: Tables: [5]; Figures: [5]
erences: 21
rd count: Text: 2198; Abstract: 250
words: COVID-19, diagnostic test, PCR, AgRDT, occupational health
hor Disclosure Statement: The authors have no competing financial interests or other conflicts of
erest

21 Abstract:

22	Introduction: The COVID-19 pandemic presents unique requirements for accessible, reliable testing, and
23	many testing platforms and sampling techniques have been developed. However, not all test methods
24	have been systematically compared to each other or a common gold standard, and the performance of
25	tests developed in the early epidemic have not been consistently re-evaluated in the context of newly
26	emerging SARS-CoV-2 variants.
27	Methods: We conducted a repeated measures study with adult healthcare workers presenting for SARS-
28	CoV-2 testing. Participants were tested using seven test modalities: PCR with samples from the
29	nasopharynx, oropharynx, and saliva; and BinaxNOW and iHealth antigen-based rapid detection tests
30	(AgRDT) sampling the oropharynx and the nares. Test sensitivity was compared using any positive PCR
31	test as the gold standard.
	D eculter 225 individuals portion and in the study. DCD tests were the most consitive with calive DCD at
32	Results: 325 individuals participated in the study. PCR tests were the most sensitive with saliva PCR at
32 33	0.957 \pm 0.048, nasopharyngeal PCR at 0.877 \pm 0.075, and oropharyngeal PCR at 0.849 \pm 0.082. Standard
33	0.957 ± 0.048, nasopharyngeal PCR at 0.877 ± 0.075, and oropharyngeal PCR at 0.849 ± 0.082. Standard
33 34	0.957 \pm 0.048, nasopharyngeal PCR at 0.877 \pm 0.075, and oropharyngeal PCR at 0.849 \pm 0.082. Standard nasal rapid antigen tests were less sensitive but roughly equivalent at 0.613 \pm 0.110 for BinaxNOW
33 34 35	0.957 \pm 0.048, nasopharyngeal PCR at 0.877 \pm 0.075, and oropharyngeal PCR at 0.849 \pm 0.082. Standard nasal rapid antigen tests were less sensitive but roughly equivalent at 0.613 \pm 0.110 for BinaxNOW brand and 0.627 \pm 0.109 for iHealth. Oropharyngeal rapid antigen tests were the least sensitive with
33 34 35 36	0.957 \pm 0.048, nasopharyngeal PCR at 0.877 \pm 0.075, and oropharyngeal PCR at 0.849 \pm 0.082. Standard nasal rapid antigen tests were less sensitive but roughly equivalent at 0.613 \pm 0.110 for BinaxNOW brand and 0.627 \pm 0.109 for iHealth. Oropharyngeal rapid antigen tests were the least sensitive with BinaxNOW and iHealth brands at 0.400 \pm 0.111 and 0.311 \pm 0.105 respectively.
33 34 35 36 37	0.957 \pm 0.048, nasopharyngeal PCR at 0.877 \pm 0.075, and oropharyngeal PCR at 0.849 \pm 0.082. Standard nasal rapid antigen tests were less sensitive but roughly equivalent at 0.613 \pm 0.110 for BinaxNOW brand and 0.627 \pm 0.109 for iHealth. Oropharyngeal rapid antigen tests were the least sensitive with BinaxNOW and iHealth brands at 0.400 \pm 0.111 and 0.311 \pm 0.105 respectively. Conclusion: PCR remains the most sensitive testing modality for COVID-19, with saliva PCR being
 33 34 35 36 37 38 	0.957 ± 0.048, nasopharyngeal PCR at 0.877 ± 0.075, and oropharyngeal PCR at 0.849 ± 0.082. Standard nasal rapid antigen tests were less sensitive but roughly equivalent at 0.613 ± 0.110 for BinaxNOW brand and 0.627 ± 0.109 for iHealth. Oropharyngeal rapid antigen tests were the least sensitive with BinaxNOW and iHealth brands at 0.400 ± 0.111 and 0.311 ± 0.105 respectively. Conclusion: PCR remains the most sensitive testing modality for COVID-19, with saliva PCR being significantly more sensitive than oropharyngeal PCR and equivalent to nasopharyngeal PCR. Saliva

3

43 Introduction

The dramatic appearance of the highly transmissible SARS-CoV-2 pandemic on the world stage in late 44 2019 created an urgent need for rapid, point-of-care diagnostic tests that could accurately detect 45 infectious cases. By 2022, a wide range of testing modalities had been developed, generally relying on 46 either nucleic acid amplification (NAAT) or detection of viral antigens by lateral flow chromatography 47 48 (antigen rapid diagnostic tests, or Ag-RDTs). NAAT-based tests are generally regarded as the most 49 sensitive testing modality but require laboratory processing, have longer result turnaround times, and may yield false positive results in those with recent resolved infection. Use of at-home Ag-RDTs has been 50 widespread, with 20% of individuals reporting use of one of these tests during the last 30 days during 51 the period of omicron variant dominance (omicron wave)¹. Pre-omicron data showed sensitivity of a 52 single Ag-RDT to be approximately 70%, with positive correlation between higher viral load as estimated 53 by Ct values and sensitivity²⁻⁴. Early studies during the omicron wave show varied sensitivity between 54 Ag-RDT brands⁵, with some such as the BinaxNOW showing maintained sensitivity of around 65%⁶. 55 Other brands such as iHealth have shown similar sensitivity in detecting delta and omicron variants in 56 57 the laboratory but have not been as widely validated in epidemiologic studies during the delta and omicron waves⁷. 58

59

Several additional factors may affect this performance. Many of these tests were developed and
 validated before the emergence of B.1.1.529 (omicron) variants of concern and subsequent viral
 strains⁸. The rapidly evolving nature of variants and subvariants of SARS-CoV-2 lead to questions
 regarding the validity of previously developed tests with virus changes that may affect viral load or
 optimal test sample source. Site of testing is another important variable. For NAATs, the most common
 of which use polymerase chain reaction (PCR) technology, a variety of sample sources have been
 evaluated including nasopharyngeal swabs (NP), oropharyngeal swabs (OP), and saliva samples. Pre-

67	omicron meta-analyses showed either equivalence in saliva and NP testing ⁹ , or slightly increased
68	sensitivity of NP testing compared with saliva ¹⁰⁻¹² . However, some studies involving early omicron
69	strains showed better sensitivity with saliva swabs compared to mid-turbinate swabs ^{13,14} . NP testing is
70	more costly than saliva and can be associated with significant discomfort. ¹⁵ The standard collection site
71	for AgRDTs is the bilateral nares ^{16,17} , but the evidence of better PCR sensitivity in saliva compared to NP
72	raises the question of whether OP AgRDT testing could provide equal or better sensitivity. Given the
73	many available testing platforms and testing sites, lack of standardization between methods, and
74	significant issues relating to cost, performance, and patient experience, we performed a repeated-
75	measures observational study in a sample of adult healthcare workers presenting consecutively for
76	SARS-CoV-2 testing at the Oregon Health and Sciences University Occupational Health clinic.
77	
78	Methods:
78 79	Methods: Regulatory approval: This study was performed with informed consent from all participating individuals,
79	Regulatory approval: This study was performed with informed consent from all participating individuals,
79 80	<i>Regulatory approval</i> : This study was performed with informed consent from all participating individuals, with approval and regulatory oversight by the Oregon Health and Sciences University institutional
79 80 81	<i>Regulatory approval</i> : This study was performed with informed consent from all participating individuals, with approval and regulatory oversight by the Oregon Health and Sciences University institutional
79 80 81 82	<i>Regulatory approval</i> : This study was performed with informed consent from all participating individuals, with approval and regulatory oversight by the Oregon Health and Sciences University institutional review board.
79 80 81 82 83	Regulatory approval: This study was performed with informed consent from all participating individuals, with approval and regulatory oversight by the Oregon Health and Sciences University institutional review board. Recruitment: We designed a repeated measures study evaluating PCR tests, iHealth Ag-RDTs, and
79 80 81 82 83 84	Regulatory approval: This study was performed with informed consent from all participating individuals, with approval and regulatory oversight by the Oregon Health and Sciences University institutional review board. Recruitment: We designed a repeated measures study evaluating PCR tests, iHealth Ag-RDTs, and BinaxNOW Ag-RDTs at the OHSU Occupational Health Testing Site. Between January 25, 2022 and
79 80 81 82 83 84 85	Regulatory approval: This study was performed with informed consent from all participating individuals, with approval and regulatory oversight by the Oregon Health and Sciences University institutional review board. Recruitment: We designed a repeated measures study evaluating PCR tests, iHealth Ag-RDTs, and BinaxNOW Ag-RDTs at the OHSU Occupational Health Testing Site. Between January 25, 2022 and March 4, 2022, individuals presenting for SARS-CoV-2 testing for any reason at OHSU Occupational
79 80 81 82 83 84 85 86	Regulatory approval: This study was performed with informed consent from all participating individuals, with approval and regulatory oversight by the Oregon Health and Sciences University institutional review board. Recruitment: We designed a repeated measures study evaluating PCR tests, iHealth Ag-RDTs, and BinaxNOW Ag-RDTs at the OHSU Occupational Health Testing Site. Between January 25, 2022 and March 4, 2022, individuals presenting for SARS-CoV-2 testing for any reason at OHSU Occupational Health were approached consecutively and offered screening for enrollment on a first-come-first-serve

It is made available under a CC-BY-NC 4.0 International license .

5

swab, saliva sample); BinaxNOW Ag-RDT (nasal swab, oropharyngeal swab); and IHealth Ag-RDT (nasal
swab, oropharyngeal swab).

93	PCR testing: Researchers collected NP and OP swabs from participants in accordance with CDC
94	guidelines ¹⁸ . For saliva testing, participants were required to not eat or drink anything for 30 minutes
95	prior to sample collection. They were then directed to spit the saliva that pooled in the bottom of their
96	mouth into the collection tube until it reached the volume specified by the manufacturer. Saliva samples
97	were stored on ice and all samples were transported to the OHSU Molecular Microbiology Laboratory
98	for testing on the day of collection. Viral RNA was extracted using the King Fisher MagMAX
99	Viral/Pathogen Nucleic Acid Isolation Kit, then samples were tested using Taqpath™ COVID-19 Multiplex
100	RT-PCR which targets the Covid-19 S-gene, N-gene, and ORF1ab. A positive test result required positive
101	readings in 2/3 targets at a cycle threshold <40.
102	
103	AgRDT testing: Researchers collected and ran nasal swabs in accordance with manufacturer
104	specifications ^{16,17} , except that samples were collected and tested outdoors at ambient temperatures
105	ranging from 40-60°F (manufacturer suggest testing at "room temperature"). OP Ag-RDT samples were
106	collected in accordance with CDC OP guidelines and samples were run otherwise in accordance with
107	manufacturer guidelines. All samples were read out after the recommended run time by the collecting
108	researcher.
109	
110	Statistical Analysis: Symptom data, test results, and sequencing data were described using frequencies
111	and percentages. Likelihood ratios for symptoms and pairs of symptoms were calculated from
112	contingency tables. Using a positive test on any PCR test as the gold standard, contingency tables were
113	generated for each testing modality, and sensitivities and specificities were calculated. McNemar's test

It is made available under a CC-BY-NC 4.0 International license .

6

was used for P-values. A P-value of <0.05 was considered statistically significant. Statistical analyses
 were conducted using Python version 3.10.8.

116

117 Data agreement: all deidentified data will be made publicly available on request by writing to

- 118 tornberg@ohsu.edu.
- 119
- 120 **Results:**

121 Patients and samples: 325 individuals participated in this study. Six were not tested with BinaxNOW kits

due to supply shortages, one did not receive OP iHealth testing due to user error, and 32 were not

tested in saliva due to eating or drinking within 30 minutes of the time of testing. All others were tested

using all testing modalities. 75 individuals were positive on at least one test; 8 individuals were positive

125 on a single test; 19 individuals were positive on 1 or more PCR tests but negative on all antigen rapid

detection tests; 0 were negative on all PCR tests but positive on one or more AgDT; and 13 individuals

were positive on all tests performed. Distribution of number of positive tests per individual and types of

positive tests per number of positive test are shown in figures 1 and 2.

129

Symptoms: 27 different symptoms were reported across all (A) participants. 16 of these were reported
in individuals that tested positive (P) (table 1). Sore throat (A = 23.8%, P = 21.3%), cough (A = 12.6, P =
20.0), and headache (A = 11.8, P = 11.1) were the most commonly reported symptoms for both A and P
participants. Likelihood ratios (LR) for single symptoms ranged from 0.00 (nausea) to 3.33 (fever) (Table
Likelihood ratios of a positive test were highest for the combinations of chills and cough (26.7), fever
and headache (5.3), and headache and cough (5.2) (Table 3).

137	Test Sensitivity and Specificity: Test sensitivity ranged from 0.311 ± 0.105 for OP iHealth to 0.957 ± 0.048
138	for saliva PCR. Test specificity was 1 (Table 4) for all tests examined. Among individuals positive by any
139	PCR, 68.0% were positive on all three PCR tests (Figure 3) and among those positive for one or more PCR
140	tests, 74.7% had at least one positive AgRDT. Individuals positive on any PCR were positive on at least
141	one nasal AgRDT and at least one OP AgRDT 34.7% of the time, positive on at least one nasal AgRDT but
142	no OP AgRDTs 28.0% of the time, and positive on at least one OP AgRDT but no nasal AgRDTs 12.0% of
143	the time (Figure 4). Sensitivities of PCR tests were significantly higher than AgRDTs (all p<0.0001). There
144	were no significant differences in performance between BinaxNow and iHealth, for either nasal
145	swabbing (p=1.0) or OP swabbing (p=0.14). With respect to testing method: Nasal AgRDTs tests were
146	more sensitive than OP AgRDTs (all p<0.01). Saliva PCR was significantly more sensitive than OP PCR
147	(p<0.05), and trended towards greater sensitivity than NP PCR, though this did not reach significance
148	(p=0.11). NP and OP PCR testing were not significantly different (Figure 5).
149	
150	Sequenced Lineages: 115 samples (including multiple samples from individual participants) were
150 151	Sequenced Lineages: 115 samples (including multiple samples from individual participants) were sequenced for Pango Lineage and Nextstrain Clade (Table 5) yielding 8 viral strains by Pango lineage.
151	sequenced for Pango Lineage and Nextstrain Clade (Table 5) yielding 8 viral strains by Pango lineage.
151 152	sequenced for Pango Lineage and Nextstrain Clade (Table 5) yielding 8 viral strains by Pango lineage.
151 152 153	sequenced for Pango Lineage and Nextstrain Clade (Table 5) yielding 8 viral strains by Pango lineage. Ba.1.1 and 21K (Omicron) were the most common, respectively.
151 152 153 154	sequenced for Pango Lineage and Nextstrain Clade (Table 5) yielding 8 viral strains by Pango lineage. Ba.1.1 and 21K (Omicron) were the most common, respectively.
151 152 153 154 155	sequenced for Pango Lineage and Nextstrain Clade (Table 5) yielding 8 viral strains by Pango lineage. Ba.1.1 and 21K (Omicron) were the most common, respectively. Discussion: We compared seven test modalities for the diagnosis of COVID-19 in 325 participants. We found that
151 152 153 154 155 156	sequenced for Pango Lineage and Nextstrain Clade (Table 5) yielding 8 viral strains by Pango lineage. Ba.1.1 and 21K (Omicron) were the most common, respectively. Discussion: We compared seven test modalities for the diagnosis of COVID-19 in 325 participants. We found that PCR tests were the most sensitive, nasal AgRDTs were moderately sensitive, and OP AgRDTs were the
151 152 153 154 155 156 157	sequenced for Pango Lineage and Nextstrain Clade (Table 5) yielding 8 viral strains by Pango lineage. Ba.1.1 and 21K (Omicron) were the most common, respectively. Discussion: We compared seven test modalities for the diagnosis of COVID-19 in 325 participants. We found that PCR tests were the most sensitive, nasal AgRDTs were moderately sensitive, and OP AgRDTs were the least sensitive. Prior meta-analyses showed single AgRDTs to have a sensitivity of approximately 70%,

It is made available under a CC-BY-NC 4.0 International license .

8

162	Site of testing was also an important factor. Saliva tests were significantly more sensitive than OP tests,
163	but NP tests were not significantly different from saliva or OP tests. This is consistent with prior research
164	on the Omicron variant ¹⁴ . Saliva tests are less uncomfortable and less expensive than NP tests ^{9,15} , which
165	combined with their equal sensitivity to NP tests would appear to make them a preferred test method.
166	One downside to saliva testing is the need for participants to abstain from eating or drinking for 30
167	minutes prior to testing. During major infection waves such as Omicron, maximizing testing throughput
168	was important, and a 30-minute wait time could be problematic. However, saliva testing can be
169	performed by lay individuals, or even as part of an unsupervised "drop-box" collection system, and could
170	also represent a substantial benefit when testing in the pediatric population.
171	
172	Use of oropharyngeal swabbing for AgRDTs is a non-standard technique, which in this study yielded
173	lower sensitivity than nasal AgRDTs. Nevertheless, 9 out of 75 positive participants were positive on at
174	least one OP AgRDT, but negative on both nasal AgRDTs, highlighting considerable test performance
175	variability by swabbing site. The reason for this discrepancy is unknown, and could represent variability
176	in individual test kit performance, technical factors during swabbing and/or actual site-specific biological
177	variability in shedding of viral antigens. This observation raises the question as to whether sensitivity
178	during point-of-care or home use of AgRDTs might be optimized by the use of both an oral and a nasal
179	swab during testing. A study by Goodall et al. in 2022 examining the use of OP swabs and combined
180	nasal/throat swabs during the omicron wave found different results, with both NP and OP swabs having
181	0.645 sensitivity compared to PCR ¹⁹ . They also found that combined nasal/throat swabs had an
182	increased sensitivity compared to PCR at 0.887. Important differences between this study and our work
183	include their use of asymptomatic participants, RT-PCR from residual viral media, Panbio brand tests,

It is made available under a CC-BY-NC 4.0 International license .

9

and sample self-collection. More research is needed to elucidate potential benefits of OP swabs in
 conjunction with nasal swabs and/or utility of combined nasal/throat swabs.

186

While early predictive models had found loss of taste and smell, fatigue, cough, and anorexia to be 187 highly correlated with a positive COVID-19 test²⁰, in our series Individual symptoms most predictive of a 188 positive test were cough, chills, and fever, with chills and cough being the most significant predictive 189 190 pair of a positive test. Loss of taste and smell were not commonly reported symptoms in our dataset, and fatigue was quite common but less predictive than many other symptoms. Other studies performed 191 during prevalence of the Omicron variant reported patterns of symptomatology with those observed 192 here²¹, underscoring the need for continued surveillance and clinical research during the evolution of a 193 194 viral pandemic. Among 115 samples yielding viral genomic sequences, 82 were BA.1.1, and all were within the Omicron family, suggesting most infections in our cohort were due to the omicron variant. A 195 comparative assessment of symptoms and test performance by viral strain was therefore not possible. 196 197

This study has several limitations. During data collection, some AgRDTs tests were run at outside 198 ambient seasonal temperatures ranging from 36°F – 60°F. This complies with storage recommendations 199 200 for both brands (35.6°F and 86°F). However, iHealth manufacturer instructions recommend running the assays between 65-86 °F, and slightly colder temperatures in our "real-world setting" may have affected 201 test performance. Our data set only included one asymptomatic positive individual, who was positive 202 on all three PCR tests negative on all AgRDTs. A 2023 meta-analysis showed decreased sensitivity at 203 42.6% when AgRDTs were used as screening tools in the general population⁴. AgRDTs therefore may be 204 most valuable for maximizing early detection of COVID-19 in symptomatic individuals but should not be 205 relied on exclusively for all testing purposes. 206

It is made available under a CC-BY-NC 4.0 International license .

208	Conclusion: PCR COVID-19 tests are the most sensitive, and should remain the gold standard for COVID-
209	19 detection. Testing by PCR in saliva is more sensitive than PCR using OP samples, and offers financial,
210	operational, and patient comfort advantages compared to NP tests. AgRDTs are less sensitive than PCR
211	tests. AgRDTs conducted in the standard nasal manner are more sensitive than AgRDTs conducted with
212	oropharnygeal samples. Differences in both test sensitivity and COVID-19 symptom presentation
213	between our data and older, pre-Omicron data reinforce the need for continued assessment of tests and
214	risk stratification tools as pandemics evolve.
215	
216	
217	

- 218
- ___

It is made available under a CC-BY-NC 4.0 International license .

219 Acknowledgments

220	We gratefully acknowledge the Occupational Health team, including Kira Loken, Skylar Workinger,

- Andrea Dayot, Natlie Dutro, and the rest of the occupational health team. We are grateful for the
- assistance of Oregon National Guard members Austin Krause, Charlie Jedda, and Jack Kelly. We thank
- the OHSU Molecular Microbiology Lab for support with laboratory testing, the Oregon Health Authority
- for providing additional rapid antigen tests and medical student researchers Mikaela Siegel, Emily
- Burney, Ying Yu, and Lynn Bajorek for assistance with recruiting and testing. Lastly, we are especially
- appreciative of the OHSU workforce members for their extraordinary generosity in participating in this
- 227 study.
- 228
- 229 Funding
- 230 This study was supported by the OHSU Department of Occupational Health and the OHSU School of
- 231 Medicine.
- 232

233 Tables

	All Par	ticipants	Positive Participants		
Symptom	Number reporting	Proportion reporting	Number reporting	Proportion reporting	
sore throat	165	0.2381	46	0.2130	
cough	87	0.1255	43	0.1991	
headache	82	0.1183	24	0.1111	
congestion	74	0.1068	18	0.0833	
fatigue	60	0.0866	12	0.0556	
body aches	60	0.0866	23	0.1065	
rhinorrhea	43	0.0620	8	0.0370	
fever	36	0.0519	18	0.0833	
chills	21	0.0303	10	0.0463	
nausea	12	0.0173			
diarrhea	9	0.0130			
shortness of breath	6	0.0087	3	0.0139	
chest tightness	5	0.0072	2	0.0093	
dizziness	5	0.0072	2	0.0093	
sneezing	4	0.0058	1	0.0046	
loss of smell	4	0.0058	2	0.0093	
vomiting	3	0.0043			
ear pain	3	0.0043	2	0.0093	
sinus pressure	3	0.0043	1	0.0046	
hot flashes	2	0.0029			
stuffy nose	2	0.0029			
gastrointestinal	2	0.0029			
neck stiffness	1	0.0014			
loss of taste	1	0.0014			
night sweats	1	0.0014	1	0.0046	
loss of appetite	1	0.0014			
insomnia	1	0.0014			

Table 1: Symptoms Reported by All/Positive participants. Total number of participants reporting each symptom is reported on the left side of each pair, with percentage in that category listed on the right.

It is made available under a CC-BY-NC 4.0 International license .

13

Symptom	Likelihood ratio
sore throat	1.289
cough	3.258
headache	1.379
congestion	1.071
fatigue	0.833
body aches	2.037
runny nose	0.762
fever	3.333
chills	3.030
nausea	0.000

Table 2: Likelihood ratio of a positive vs anegative test

235

It is made available under a CC-BY-NC 4.0 International license .

14

	sore throat	cough	headac he	conges tion	fatigue	body aches	runny nose	fever	chills	gi	nausea
sore throat											
cough	3.60										
headache	1.35	5.15									
congestion	0.93	3.33	1.78								
fatigue	0.77	2.14	1.11	0.63							
body aches	2.63	3.94	2.04	0.71	0.71						
runny nose	0.53	0.95	0.37	0.00	1.67	0.95					
fever	4.07	5.00	5.33	2.22	0.67	2.50	0.00				
chills	2.78	26.67	3.33	2.00	0.56	2.67	3.33	4.44			
gi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
nausea	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.00	

Table 3: Likelihood Ratios for Positive Tests of Paired Symptoms.

237

It is made available under a CC-BY-NC 4.0 International license .

Test	Sensitivity	Specificity
OP BinaxNOW	0.400 ± 0.111	1.000 ± 0.000
OP iHealth	0.311 ± 0.105	1.000 ± 0.000
Nasal BinaxNOW	0.613 ± 0.110	1.000 ± 0.000
Nasal iHealth	0.627 ± 0.109	1.000 ± 0.000
NP PCR	0.877 ± 0.075	1.000 ± 0.000
OP PCR	0.849 ± 0.082	1.000 ± 0.000
Saliva PCR	0.957 ± 0.048	1.000 ± 0.000

Table 4: Sensitivity and Specificity of all testsmeasured against any positive PCR as goldstandard.

It is made available under a CC-BY-NC 4.0 International license .

16

240

	Pango lineage		Nextstrain clade
BA.1.1	82	21K (Omicron)	111
BA.1.15	9	21L (Omicron)	4
BA.1.20	8		
BA.1.1.18	4		
BA.2	4		
BA.1.17	4		
BA.1	2		
BA.1.17.2	2		


Table 5: Number of samples in each Pango lineage andNextstrain clade.

241


It is made available under a CC-BY-NC 4.0 International license .


17

Figures 243



244





Distribution of test methods by number of positive tests

Figure 2: Distribution of test methods by number of positive tests.





Figure 3: PCR test positivity breakdown in participants with a positive PCR test that 1 or more sites.

It is made available under a CC-BY-NC 4.0 International license .

250


Figure 4: Antigen rapid detection test positivity breakdown in participants with 1 or more positive PCR 251

252 tests.



It is made available under a CC-BY-NC 4.0 International license .

20



253

Figure 5: Sensitivities of All Tests. "n.s." denotes no significant difference between tests. "*" denotes
 significant difference with p<0.05. All other comparisons not marked are significantly different with
 p<0.01.

257

21

259 References

Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States, August 23, 1. 261 2021-March 12, 2022. MMWR Morb Mortal Wkly Rep. Apr 1 2022;71(13):489-494. doi:10.15585/mmwr.mm7113e1 262 Brummer LE, Katzenschlager S, McGrath S, et al. Accuracy of rapid point-of-care antigen-based 263 2. diagnostics for SARS-CoV-2: An updated systematic review and meta-analysis with meta-regression 264 analyzing influencing factors. PLoS Med. May 2022;19(5):e1004011. doi:10.1371/journal.pmed.1004011 Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for 266 3. diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. Mar 24 2021;3:CD013705. 267 doi:10.1002/14651858.CD013705.pub2 268 4. Fragkou PC, Moschopoulos CD, Dimopoulou D, et al. Performance of point-of care molecular 269 270 and antigen-based tests for SARS-CoV-2: a living systematic review and meta-analysis. Clin Microbiol Infect. Mar 2023;29(3):291-301. doi:10.1016/j.cmi.2022.10.028 271 Bekliz M P-RF, Puhach O, et al. Sensitivity of SARS-CoV-2 antigen-detecting rapid tests for 272 5. 273 Omicron variant. medRxiv2022. Schrom JM, C.; Pilarowski, G.; et al. Comparison of SARS-CoV-2 Reverse Transcriptase 6. 274 Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community Site During an Omicron 275 Surge. Annals of Internal Medicine. 2022;175(5):682-690. doi:10.7326/m22-0202 %m 35286144 276 7. Kanjilal S, Chalise S, Shah AS, et al. Performance of three rapid antigen tests against the SARS-277 CoV-2 Omicron variant. medRxiv. 2022:2022.02.17.22271142. doi:10.1101/2022.02.17.22271142 278 279 8. Drain PK. Rapid Diagnostic Testing for SARS-CoV-2. N Engl J Med. Jan 20 2022;386(3):264-272. doi:10.1056/NEJMcp2117115 280 Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs of Testing for 9. 281 SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-282 analysis. Ann Intern Med. Apr 2021;174(4):501-510. doi:10.7326/M20-6569 283 Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of Saliva, 10. 284 285 Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a Systematic Review and 286 Meta-analysis. J Clin Microbiol. Apr 20 2021;59(5)doi:10.1128/JCM.02881-20 11. Ibrahimi N, Delaunay-Moisan A, Hill C, et al. Screening for SARS-CoV-2 by RT-PCR: Saliva or 287 nasopharyngeal swab? Rapid review and meta-analysis. PLoS One. 2021;16(6):e0253007. 288 doi:10.1371/journal.pone.0253007 289 290 12. Duncan DB, Mackett K, Ali MU, Yamamura D, Balion C. Performance of saliva compared with nasopharyngeal swab for diagnosis of COVID-19 by NAAT in cross-sectional studies: Systematic review 291 and meta-analysis. Clin Biochem. Jul 2023;117:84-93. doi:10.1016/j.clinbiochem.2022.08.004 292 13. Marais G, Hsiao NY, Iranzadeh A, et al. Improved oral detection is a characteristic of Omicron 293 infection and has implications for clinical sampling and tissue tropism. J Clin Virol. Jul 2022;152:105170. 294 295 doi:10.1016/j.jcv.2022.105170 Ursic T, Kogoj R, Sikonja J, et al. Performance of nasopharyngeal swab and saliva in detecting 296 14. Delta and Omicron SARS-CoV-2 variants. J Med Virol. Jun 1 2022;doi:10.1002/jmv.27898 297 Moisset X, Gautier N, Godet T, et al. Nasopharyngeal swab-induced pain for SARS-CoV-2 15. 298 screening: A randomised controlled trial of conventional and self-swabbing. Eur J Pain. Apr 299 2021;25(4):924-929. doi:10.1002/ejp.1722 300 Abbott. BinaxNOW COVID-19 Ag Card - Instructions for Use. Abbott. Accessed September 22, 16. 301 2022. 302 iHealth. iHealth COVID-19 Antigen Rapid Test - Instruction for Use Home Testing. Accessed 17. 304 September 22, 2022.

It is made available under a CC-BY-NC 4.0 International license .

18. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing.
 Centers for Disease Control and Prevention. Updated 15 July 2022. Accessed 7 July 2022, 2022.

19. Goodall BL, LeBlanc JJ, Hatchette TF, Barrett L, Patriquin G. Investigating the Sensitivity of Nasal

308 or Throat Swabs: Combination of Both Swabs Increases the Sensitivity of SARS-CoV-2 Rapid Antigen

309 Tests. *Microbiol Spectr*. Aug 31 2022;10(4):e0021722. doi:10.1128/spectrum.00217-22

20. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict

 311
 potential COVID-19. Nat Med. Jul 2020;26(7):1037-1040. doi:10.1038/s41591-020-0916-2

 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 21
 2

21. Petersen MS, S IK, Eliasen EH, et al. Clinical characteristics of the Omicron variant - results from a

Nationwide Symptoms Survey in the Faroe Islands. *Int J Infect Dis*. Sep 2022;122:636-643.

doi:10.1016/j.ijid.2022.07.005